OOIR: Observatory of International Research

Papers

(The H4-Index of Oncoimmunology is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells	86
Ferroptosis: friend or foe in cancer immunotherapy?	83
ADAM12 abrogation alters immune cell infiltration and improves response to checkpoint blockade therapy in the T11 murine model of triple-negative breast cancer	73
The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers?	53
Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity	52
Dipeptidyl peptidase 4 inhibition sensitizes radiotherapy by promoting T cell infiltration	51
HIF2A mediates lineage transition to aggressive phenotype of cancer-associated fibroblasts in lung cancer brain metastasis	48
Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patients	48
A targeted MAVS fusion protein for controlled innate immune activation and antitumor therapy	46
Nanoparticles releasing immunogenic cell death inducers upon near-infrared light exposure	45
CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2	45
Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer	43
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression	40
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment	39
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors	39
Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype	35
DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway	34
Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis	34
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment	34
The ART of tumor immune escape	33
A novel membrane-bound interleukin-2 promotes NK-92 cell persistence and anti-tumor activity	32
Dissecting the cellular components of ex vivo γδ T cell expansions to optimize selection of potent cell therapy donors for neuroblastoma immunotherapy trials	32
Antibody–drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties	32
Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response	30
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer	30

Characterisation of the tumour microenvironment and PD-L1 granularity reveals the prognostic value of cancer-associated myofibroblasts in non-invasive bladder cancer	28
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint in	28
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7 ^th immunorad conference	27
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)	27